Apoptosis

Fibrinolysis and Proteolysis

Volumn 14, Issue 2-3, 2000, Pages 82-86

  Nagata, S ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DNA FRAGMENT; FAS ANTIGEN; FAS LIGAND; PERFORIN; PROTEIN BCL 2;

APOPTOSIS; CELL DEATH; CELLULAR IMMUNITY; DEVELOPMENT; HOMEOSTASIS; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034049761     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1054/fipr.2000.0074     Document Type: Review

References (38)

1. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
2. Raff M. Cell suicide for beginners. Nature 1998; 396: 119-122.
3. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
4. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
5. Ellis HM, Horvitz H. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44: 817-829.
6. Peter ME, Heufflder AE, Hengartner MO. Advances in apoptosis research. Proc Natl Acad Sci USA 1997; 94: 12736-12737.
7. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997; 22: 299-306.
8. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316.
9. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
10. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999; 96: 245-254.
11. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
12. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
13. Gruss H-J, Dower S. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphoma. Blood 1995; 85: 3378-3404.
14. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genetics 1999; 33: 29-55.
15. Krammer P. CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv Immunol 1999; 71: 163-210.
16. Nagata S. Biddable death. Nat Cell Biol 1999; 1: E143-E145.
17. Herzog KH, Chong MJ, Kapsetaki M, Morgan JI, McKinnon PJ. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 1998; 280: 1089-1091.
18. Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity 1999; 10: 629-639.
19. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555-556.
20. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis and its inhibitor ICAD. Nature 1998; 391: 43-50.
21. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000; 256: 12-18.
22. Sakahira H, Iwamatsu A, Nagata S. Specific chaperone-like activity of inhibitor of caspase-activated DNase for caspase-activated DNase. J Biol Chem 2000; 275: 8091-8096.
23. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998; 391: 96-99.
24. McIlroy D, Tanaka M, Sakahira H et al. An auxiliary mode of apoptotic DNA fragmentation provided by phagocytes. Genes & Develop 2000; 14: 549-558.
25. Stroh C, Schulze-Osthoff K. Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Diff 1998; 5: 997-1000.
26. Mukae N, Yokoyama H, Yokokura T, Sakoyama Y, Sakahira H, Nagata S. Identification and developmental expression of inhibitor of caspase-activated DNase (ICAD) in Drosophila melanogaster. J Biol Chem 2000; in press.
27. Yokoyama H, Mukae N, Sakahira H, Okawa K, Iwamatsu A, Nagata S. A novel activation mechanism of caspase-activated DNase from Drosophila melanogaster. J Biol Chem 2000; 275: 12978-12986.
28. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: 243-269.
29. Nagata S, Suda T. Fas and Fas ligand: Ipr and gld mutations. Immunol Today 1995; 16: 39-43.
30. Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J Hum Genet 1998; 43: 2-8.
31. Gronbaek K, Straten PT, Ralfkiaer E et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998; 92: 3018-3024.
32. Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90: 4266-4270.
33. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997; 186: 785-793.
34. Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
35. Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
36. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183: 657-661.
37. Barinaga M. Is apoptosis key in Alzheimer's disease? Science 1998; 281: 1303-1304.
38. Cheng Y, Deshmukh M, D'Costa A et al. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest 1998; 101: 1992-1999.